BIOMAT Database Logo BIOMAT Database Logo

Amphotericin B in resistant visceral leishmaniasis. 1996

A S Sahay, and T K Jha
Department of Medicine, S.K. Medical College, Muzaffarpur.

UI MeSH Term Description Entries
D007896 Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL). Leishmania Infection,Infection, Leishmania,Infections, Leishmania,Leishmania Infections,Leishmaniases
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

A S Sahay, and T K Jha
Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
May 1991, Lancet (London, England),
A S Sahay, and T K Jha
Amphotericin B in visceral leishmaniasis.
November 1996, Indian pediatrics,
A S Sahay, and T K Jha
Amphotericin B in visceral leishmaniasis.
January 1993, Indian pediatrics,
A S Sahay, and T K Jha
[Visceral leishmaniasis resistant to conventional treatments: value of amphotericin B].
October 1993, Pathologie-biologie,
A S Sahay, and T K Jha
Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B.
January 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene,
A S Sahay, and T K Jha
Amphotericin B for visceral leishmaniasis in hemodialysis.
January 1991, Nephron,
A S Sahay, and T K Jha
Amphotericin B lipid complex: in visceral leishmaniasis.
January 2004, Drugs,
A S Sahay, and T K Jha
Amphotericin B for visceral leishmaniasis resistant to pentavalent antimonial drugs in AIDS.
November 1994, The Annals of pharmacotherapy,
A S Sahay, and T K Jha
Visceral leishmaniasis treated with liposomal amphotericin B.
January 1999, The Pediatric infectious disease journal,
A S Sahay, and T K Jha
Visceral leishmaniasis following treatment with liposomal amphotericin B.
August 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!